Võrdle meetodeid

	Patch-Clamp Elektrofsioloogia	Michaelis-Menteni kineetika	Population Pharmacodynamics	Schildi analüüs
Valdkond	Farmakoloogia	Farmakoloogia	Farmakoloogia	Farmakoloogia
Perekond	Process / pipeline	Process / pipeline	Process / pipeline	Process / pipeline
Tekkeaasta	1976	1913	1992	1947
Looja	Erwin Neher and Bert Sakmann	Leonor Michaelis and Maud Menten	Lewis Sheiner and Stephen Roush	Henry Schild
Tüüp	ion channel screening	mechanistic model	dose-response modeling	antagonism quantification
Algallikas	Neher, E., & Sakmann, B. (1976). Single-channel currents recorded from membrane of denervated frog muscle fibres. Nature, 260(5554), 799-802.	Michaelis, L., & Menten, M. L. (1913). Die Kinetik der Invertinwirkung. Biochemische Zeitschrift, 49, 333-369.	Dahlström, B., & Nyberg, L. (1993). Population pharmacokinetics and pharmacodynamics. Clinical Pharmacokinetics, 24(1), 45-57.	Schild, H. O. (1947). pA, a new scale for the measurement of drug antagonism. Journal of Physiology, 106(3), 337-357.
Rööpnimetused	patch clamp, whole-cell recording, ion channel assay	MM kinetics, Michaelis constant, Vmax	PopPD, population PD, hierarchical PD modeling	Schild plot, pA2
Seotud	3	2	3	3
Kokkuvõte	Patch-clamp electrophysiology is a technique for measuring ionic currents through ion channels in cell membranes, developed by Neher and Sakmann in 1976. It enables direct observation of single-channel and whole-cell currents at millisecond resolution, making it essential for characterizing drug effects on ion channels and cardiac safety assessment.	Michaelis-Menten kinetics describes the rate of enzyme-catalyzed reactions as a function of substrate concentration. Developed by Leonor Michaelis and Maud Menten in 1913, this foundational framework models enzyme catalysis through the rapid-equilibrium approximation and enables prediction of drug metabolism rates in pharmacokinetics.	Population pharmacodynamic (PopPD) modeling integrates pharmacokinetics with individual dose-response relationships across patient populations to characterize drug efficacy and tolerability. Pioneered by Lewis Sheiner and colleagues, PopPD accounts for inter-individual variability in drug effects and enables rational dose optimization and response prediction.	Schild analysis is a quantitative method for characterizing competitive receptor antagonism developed by Henry Schild in 1947. It uses dose-response curves in the presence and absence of antagonist to estimate the antagonist affinity constant (pA2), enabling standardized comparison of antagonist potency across drugs and experimental systems.